Expression Of GPSM2 In Pancreatic Cancer And Its Clinical Significance

Objective:To investigate G-protein signaling modulator 2(GPSM2) expression in human pancreatic cancer cells and tissues and its relationship with clinical pathological index, in order to looking for a new direction for the diagnosis and treatment of pancreatic cancer, and provide a new method for the diagnosis and treatment of pancreatic cancer. Methods:We maked the tissue microarray containing 54 pancreatic cancer samples,as well as the paired normal pancreatic tissues. The relationship between the expression of GPSM2 and the clinicopathological parameters and prognosis of the patients were analyzed by immunohistochemistry. Selected 10 cases of fresh samples of pancreatic cancer,RT-PCR were used to detect GPSM2 mRNA in pancreatic cancer and adjacent pancreatic tissues,Western blotting were used to detect the expression of GPSM2 protein in pancreatic cancer and adjacent pancreatic tissue. Results:Western blotting、 RT-PCR and immunohistochemistry were used to detect pancreatic cancer tissues and adjacent tissues,The expression of GPSM2 mRNA and protein in pancreatic cancer tissue was higher than that in normal tissues(P<0.05). Tissue microarray results showed that GPSM2 expression was significantly upregulated in pancreatic cancer tissues(P<0.05), and its high expression ratio was 74.1%. High GPSM2 expression was associated with larger tumor size(!2=12.654;P<0.05), TNM stage(!2=16.610;P<0.05)and as well as poor tumor differentiation(!2=10.355;P<0.05). Survival analysis showed that the median survival time was significantly lower in patients with high expression of GPSM2 than those with low expression(P<0.05) Conclusion:The overexpression of GPSM2 in pancreatic cancer tissues was closely related to T stage、TNM stage and poor tumor differentiation, which is related to the prognosis of the patients with pancreatic cancer.